2,2-Dichloro-N-[3-[(7-chloro-4-quinolinyl)amino]propyl]-N-methylacetamide | 1171622-88-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,2-Dichloro-N-[3-[(7-chloro-4-quinolinyl)amino]propyl]-N-methylacetamide
• 英文别名: 2,2-dichloro-N-[3-[(7-chloroquinolin-4-yl)amino]propyl]-N-methylacetamide
• CAS: 1171622-88-0
• 化学式: C₁₅H₁₆Cl₃N₃O
• 分子量: 360.7
• InChiKey: MJMIPFKUPJCIQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
  申请人：Loxo Oncology, Inc.

  公开号：US10370727B2

  公开（公告）日：2019-08-06

  Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.

  本文提供了治疗癌症受试者的方法、为癌症受试者选择治疗方法的方法、为不包括Trk抑制剂的治疗方法选择癌症受试者的方法、确定癌症受试者对Trk抑制剂治疗产生阳性反应的可能性的方法、预测Trk抑制剂对癌症受试者疗效的方法、确定受试者罹患Trk抑制剂抗性癌症风险的方法，以及根据从受试者样本中检测到的细胞具有NTRK1和/或NTRK2和/或NTRK3中至少一种点突变，确定受试者存在Trk抑制剂抗性癌症的方法。
• POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME
  申请人：The Regents of The University of Colorado, A Body Corporate

  公开号：EP3368039A1

  公开（公告）日：2018-09-05
• [EN] POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME<br/>[FR] MUTATIONS PONCTUELLES DANS LE CANCER RÉSISTANT AUX INHIBITEURS DE TRK ET MÉTHODES ASSOCIÉES
  申请人：NANDA NISHA

  公开号：WO2017075107A1

  公开（公告）日：2017-05-04

  Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
• [EN] FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO<br/>[FR] SYSTÈMES DE CULTURE DE CELLULES SOUCHES NOURRICIÈRES ET EXEMPT DE CELLULES SOUCHES NOURRICIÈRES POUR CELLULES SOUCHES ÉPITHÉLIALES STRATIFIÉES ET LEURS UTILISATIONS
  申请人：UNIV HOUSTON SYSTEM

  公开号：WO2021072238A1

  公开（公告）日：2021-04-15

  The present invention relates to a culture media system that is useful for the isolation and epigenetically stable propagation of normal stem cells in culture, wherein the stem cells are derived from stratified epithelial tissues and cancer stem cells from epithelial cancers. In certain embodiments, the culture system is a feeder-free system.